Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors

• CoMFA, CoMSIA models were developed for a series of 43 Imidazo- pyrrolopyridine derivatives.
• Molecular docking method was used to analyze possible interactions between receptors and the compounds.
• Results of the docking studies and molecular dynamics simulations complement each other.
• Seven derivatives as potential candidates of JAK1 inhibitors with good predicted activities were designed.

Janus kinase 1 (JAK 1) plays a critical role in initiating responses to cytokines by the JAK—signal transducer and activator of transcription (JAK-STAT). This controls survival, proliferation and differentiation of a variety of cells. Docking, 3D quantitative structure activity relationship (3D-QSAR) and molecular dynamics (MD) studies were performed on a series of Imidazo-pyrrolopyridine derivatives reported as JAK 1 inhibitors. QSAR model was generated using 30 molecules in the training set; developed model showed good statistical reliability, which is evident from r2ncv and r2loo values. The predictive ability of this model was determined using a test set of 13 molecules that gave acceptable predictive correlation (r2Pred) values. Finally, molecular dynamics simulation was performed to validate docking results and MM/GBSA calculations. This facilitated us to compare binding free energies of cocrystal ligand and newly designed molecule R1.The good concordance between the docking results and CoMFA/CoMSIA contour maps afforded obliging clues for the rational modification of molecules to design more potent JAK 1 inhibitors.

Janus kinase 1 (JAK 1) plays a critical role in initiating responses to cytokines by the JAK—signal transducer and activator of transcription (JAK-STAT). This controls survival, proliferation and differentiation of a variety of cells. Docking, 3D quantitative structure activity relationship (3D-QSAR) and molecular dynamics (MD) studies were performed on a series of Imidazo-pyrrolopyridine derivatives reported as JAK 1 inhibitors.Figure optionsDownload as PowerPoint slide